IN2012DN03130A - - Google Patents

Download PDF

Info

Publication number
IN2012DN03130A
IN2012DN03130A IN3130DEN2012A IN2012DN03130A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A IN 3130DEN2012 A IN3130DEN2012 A IN 3130DEN2012A IN 2012DN03130 A IN2012DN03130 A IN 2012DN03130A
Authority
IN
India
Prior art keywords
propofol
compositions
aerosols
buccal
capsules
Prior art date
Application number
Other languages
English (en)
Inventor
Bastian Theisinger
Sonja Theisinger
Original Assignee
Novaliq Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novaliq Gmbh filed Critical Novaliq Gmbh
Publication of IN2012DN03130A publication Critical patent/IN2012DN03130A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00Anaesthetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C19/00Acyclic saturated compounds containing halogen atoms
    • C07C19/08Acyclic saturated compounds containing halogen atoms containing fluorine

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IN3130DEN2012 2009-11-23 2010-11-22 IN2012DN03130A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09014548A EP2332525A1 (fr) 2009-11-23 2009-11-23 Composition pharmaceutique comprenant du propofol
PCT/EP2010/067938 WO2011061332A1 (fr) 2009-11-23 2010-11-22 Composition pharmaceutique comprenant du propofol

Publications (1)

Publication Number Publication Date
IN2012DN03130A true IN2012DN03130A (fr) 2015-09-18

Family

ID=41694756

Family Applications (1)

Application Number Title Priority Date Filing Date
IN3130DEN2012 IN2012DN03130A (fr) 2009-11-23 2010-11-22

Country Status (12)

Country Link
US (1) US8796340B2 (fr)
EP (2) EP2332525A1 (fr)
JP (1) JP5707009B2 (fr)
KR (1) KR20120104262A (fr)
CN (1) CN102753159B (fr)
AU (1) AU2010320823B2 (fr)
BR (1) BR112012012108A2 (fr)
CA (1) CA2776855C (fr)
ES (1) ES2450423T3 (fr)
IN (1) IN2012DN03130A (fr)
MX (1) MX2012005881A (fr)
WO (1) WO2011061332A1 (fr)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2564502T3 (es) 2010-03-17 2016-03-23 Novaliq Gmbh Composición farmacéutica para el tratamiento de la presión intraocular aumentada
EP2444063A1 (fr) 2010-10-20 2012-04-25 Novaliq GmbH Compositions pharmaceutiques liquides pour l'administration de principes actifs
EP2462921A1 (fr) 2010-11-11 2012-06-13 Novaliq GmbH Compositions pharmaceutiques liquides pour le traitement d'une maladie de la chambre postérieure de l'oeil
ES2962524T3 (es) 2011-05-25 2024-03-19 Dermaliq Therapeutics Inc Composición farmacéutica tópica a base de alcanos semifluorados
EP2714008B1 (fr) 2011-05-25 2016-12-14 Novaliq GmbH Composition pharmaceutique pour application sur les ongles
GB201116271D0 (en) 2011-09-21 2011-11-02 Univ Cardiff Dispersion anaesthetic device
DK2806886T3 (en) 2012-01-23 2017-06-06 Novaliq Gmbh STABILIZED PROTEIN COMPOSITIONS BASED ON SEMIFLUORED ALKANES
DK2895144T3 (en) 2012-09-12 2017-03-06 Novaliq Gmbh SEMIFLUORED ALKAN COMPOSITIONS
ES2682064T3 (es) * 2012-09-12 2018-09-18 Novaliq Gmbh Composiciones para el lavado de ojos
EP3100722B1 (fr) 2012-09-12 2024-03-20 Novaliq GmbH Alcanes semi-fluorés pour solubiliser le meibum
CN105555311B (zh) 2013-07-23 2021-10-08 诺瓦利克有限责任公司 稳定的抗体组合物
EP2944324A1 (fr) * 2014-05-13 2015-11-18 LTS LOHMANN Therapie-Systeme AG Utilisation d'alkanes semifluorés dans des systèmes d'administration transdermiques
WO2016061538A1 (fr) 2014-10-16 2016-04-21 The Board Of Trustees Of The Leland Stanford Junior University Nouveaux procédés, composés et compositions d'anesthésie
DK3355990T3 (da) 2015-09-30 2019-09-16 Novaliq Gmbh Semifluorinerede forbindelser og disses sammensætninger
DE202016008739U1 (de) 2015-09-30 2019-04-29 Novaliq Gmbh Semifluorierte Verbindungen
PT3442480T (pt) 2016-06-23 2019-12-23 Novaliq Gmbh Método de administração tópica
MX2019003363A (es) 2016-09-22 2019-10-02 Novaliq Gmbh Composiciones farmaceuticas para usarse en la terapia de la blefaritis.
MX2019003364A (es) 2016-09-23 2019-10-02 Novaliq Gmbh Composiciones oftalmicas que comprenden ciclosporina.
ES2957559T3 (es) 2017-04-21 2024-01-22 Dermaliq Therapeutics Inc Composiciones de yodo
US11278503B2 (en) 2017-05-12 2022-03-22 Novaliq Gmbh Pharmaceutical compositions comprising semifluorinated alkanes for the treatment of contact lense-related conditions
US11723861B2 (en) 2017-09-27 2023-08-15 Novaliq Gmbh Ophthalmic compositions comprising latanoprost for use in the treatment of ocular diseases
WO2019068763A1 (fr) 2017-10-04 2019-04-11 Novaliq Gmbh Compositions ophtalmiques comprenant du f6h8
KR20200128407A (ko) 2018-03-02 2020-11-12 노바리크 게엠베하 네비볼롤을 포함하는 약제학적 조성물
SG11202102820VA (en) 2018-10-12 2021-04-29 Novaliq Gmbh Ophthalmic composition for treatment of dry eye disease
EP3912622A1 (fr) 2020-05-19 2021-11-24 tesa Labtec GmbH Film oral d'administration sûre d'api

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5496537A (en) * 1995-03-23 1996-03-05 Henry; Richard A. Propofol hydrofluorocarbon propellant formulations
DE19536504C2 (de) 1995-09-29 1999-09-23 H Meinert Verwendung fluorierter Alkane
EP1124416A1 (fr) * 1999-03-15 2001-08-22 John Claude Krusz Traitement de maux de tete aigus et de douleur chronique au moyen de medicaments anesthesiques rapidement evacues dans des doses subanesthesiques
GB0124071D0 (en) * 2001-10-08 2001-11-28 Kbig Ltd Improvement in the administration of high boiling point aneasthetics
CA2549524A1 (fr) * 2004-01-02 2005-07-28 Wisconsin Alumni Research Foundation Encapsulation de composes chimiques dans des micelles a noyau fluoritique et a enveloppe interne fluoree realises a partir de copolymeres sequences semi-fluores ou fluores
DE102004030044A1 (de) 2004-06-22 2006-01-12 Birken Gmbh Triterpenhaltiger Oleogelbildner, triterpenhaltiges Oleogel und Verfahren zur Herstellung eines triterpenhaltigen Oleogels
EP2099408B1 (fr) * 2006-11-28 2016-10-05 Wisconsin Alumni Research Foundation Émulsions à base fluoropolymère pour l'administration intraveineuse d'anesthésiant volatil fluoré
PT2110126E (pt) 2008-04-18 2012-02-20 Novaliq Gmbh Utilização inalativa e instilativa de alcanos semifluorados como veículos de substância activa na região intrapulmonar

Also Published As

Publication number Publication date
JP5707009B2 (ja) 2015-04-22
WO2011061332A1 (fr) 2011-05-26
EP2332525A1 (fr) 2011-06-15
EP2503999B1 (fr) 2013-12-25
CA2776855C (fr) 2017-10-24
US20120238639A1 (en) 2012-09-20
CN102753159B (zh) 2014-03-12
US8796340B2 (en) 2014-08-05
AU2010320823B2 (en) 2014-06-26
MX2012005881A (es) 2012-06-19
CN102753159A (zh) 2012-10-24
CA2776855A1 (fr) 2011-05-26
ES2450423T3 (es) 2014-03-24
AU2010320823A1 (en) 2012-07-12
BR112012012108A2 (pt) 2016-04-05
KR20120104262A (ko) 2012-09-20
JP2013511496A (ja) 2013-04-04
EP2503999A1 (fr) 2012-10-03

Similar Documents

Publication Publication Date Title
IN2012DN03130A (fr)
MX2013001677A (es) Formulaciones estables de linaclotida.
BR112014009087A2 (pt) formulações de etanercept estabilizadas com xilitol
WO2011041729A3 (fr) Composés utiles comme antagonistes du récepteur de l'acide lysophosphatidique (lpa)
WO2011041462A3 (fr) Composés polycycliques utiles en tant qu'antagonistes du récepteur d'acide lysophosphatidique
EA201290982A1 (ru) Фармацевтические композиции, препятствующие злоупотреблению
BR112012012081A2 (pt) método para o processamento de um arquivo de imagens médicas kobitidas em um procedimento de imagem guiada por protocolo ,equipamento para o processamento de um arquivo de imagens médicas obtidas por um procedimento de imagem guiada por protocolo e elemamto de programa de computador contendo conjuntos de instruções
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
WO2011017502A3 (fr) Formulations comprenant du linaclotide
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
EA201590805A1 (ru) Композиция с немедленным и пролонгированным высвобождением
WO2010021607A3 (fr) Préparation pharmaceutique
WO2011157722A3 (fr) Composition contenant de l'ivabradine solide
WO2013134534A3 (fr) Formes à l'état solide de cabazitaxel et procédés pour les préparer
MX340147B (es) Composiciones farmacéuticas y nutracéuticas del ácido abscísico.
MY168212A (en) A new therapeutical composition containing apomorphine as active ingredient
UA110979C2 (uk) Рідка фармацевтична композиція, яка включає нітизинон
WO2011069037A3 (fr) Stabilisation et stockage de compositions pharmaceutiques biologiques
TW200718698A (en) Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof
MX2010004899A (es) Conjugados de neurturina novedosos para uso farmaceutico.
EA201200485A1 (ru) Перорально распадающаяся фармацевтическая лекарственная форма, содержащая арипипразол
WO2009140105A3 (fr) Préparations pour inhibiteurs de la cathepsine k
WO2013114400A3 (fr) Compositions pharmaceutiques comprimées d'antipsychotiques atypiques
WO2011076840A3 (fr) Préparation aérosol pour bronchopneumopathie chronique obstructive